Industry Overview
Biotechnology now stands where industry was more than a century ago. Rapid growth only started after industrial processes could be simulated mathematically. Before then progress was limited by painfully slow empirical discovery (figure 1).

Medicinal science is primarily based on empiricism. The current opportunities for biotechnology can therefore be compared to the tremendous opportunities that existed in 1900 for industrial development.

Company History
Over the past two decades we have focused on developing dynamic simulation systems for complex energy processes and their control (figure 2). This previous investment in engineering was extended to human body simulation where much more value can be added. The human body also consists of complex systems and controls. We started our biotech R&D with the dynamic simulation of the human energy (metabolic) system (figure 3). The first and critical breakthrough discovery was the concept.

All interactions in the complex human energy system (food, exercise, stress, counter regulation and insulin control, etc.) can now be related to one generic unit, . This makes full dynamic system and control simulation possible for the first time. Extensive clinical trials verified the accuracy of the simulations. Very comprehensive literature searches (450 references) showed that the successful dynamic, fully integrated simulation of the body’s energy (metabolic) system and its full controls have not been achieved before.

Potential Impact
Simulating the human energy and control system means that levels of glucose, tri-glyceride, fatty acid, etc. for any food intake, exercise, stress, drugs, counter regulation control etc., or combination thereof, can be established. It is then possible to develop better methods, diagnostic tools, products and / or pharmaceuticals to control these levels, but at a quicker pace and at a lower cost than before. Simulation is thus the key to competitiveness.

After successful computer simulation of the human carbohydrate metabolic cycle was accomplished in 2002, clinical trials were carried out to verify the predictions. Excellent results were found. Five diagnostic products, aimed at the diabetic and bariatric (weight loss) markets, were then developed based on the discoveries and insight gained. All were patented.

Our Future
We believe that based on our initial success with these preliminary dynamic energy simulations we have potentially found the key to accurately simulate other body systems and their controls. Our company's technology vision is therefore to simulate, fully integrated and dynamically, the full metabolic systems and their controls. Insight gained through this simulation will lead to rapid development of novel spin-off products for the healthcare market.

Our long-term business objective is to establish a strong business through partnerships using our lead in simulation as a competitive edge for biotechnology and pharmaceutical product development.

Figure 1 Industry history

Figure 2 Energy simulation

Figure 3 Human energy system